Measurement of MMP-14 Protein, a Potential New Marker for Colorectal Cancer Detection, in Plasma Vesicles Named Exosomes

Launched by CHU DE REIMS · May 1, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new potential marker called MMP-14 that could help in the early detection of colorectal cancer. Colorectal cancer is a common type of cancer, and current screening methods often lead to many unnecessary colonoscopies, as most results come back negative. The researchers believe that measuring MMP-14 levels in blood samples (specifically in tiny particles called exosomes released by cancer cells) could improve screening and reduce the number of unnecessary procedures.

To be eligible for the trial, participants must be adults who have tested positive on a fecal immunochemical test (FIT) and are scheduled for a colonoscopy. They will need to agree to participate in the study and sign a consent form. During the trial, blood will be collected to measure MMP-14 levels, and these results will be compared with the findings from their colonoscopy to assess how well MMP-14 can indicate the presence of colorectal cancer or adenomas (non-cancerous growths). This study aims to find the best cutoff level for MMP-14 that could help screen for these conditions more effectively.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Individuals presenting for colonoscopy with a positive FIT result.
• • Positive fecal immunoassay requiring total colonoscopy under general anesthesia.
• • Persons having agreed to participate in the study (signed consent form)
• • Adults affiliated to a health insurance scheme.
• Exclusion criteria:
• • History of other cancer not in remission or in remission for less than five years (with the exception of cervical cancer or basal cell skin cancer treated with curative intent)
• • Patients undergoing chemotherapy
• • Legally protected individuals